A Pilot Study of Whether the Cold-Heat Syndrome Type is Associated with Treatment Response and Immune Status in Patients with Non-Small Cell Lung Cancer

Table 2

Cytokines and immune profiling of 10 patients with non-cold or cold type.

	Non-cold (n = 5)	Cold (n = 5)	value
Age (year)	55.6 ± 12.9	68.8 ± 8.3	0.091
Sex	—	—	0.168
Female	0 (0.0%)	3 (60.0%)
Male	5 (100.0%)	2 (40.0%)
Cytokine (pg/mL)
IL-6 (n = 9)	3.8 ± 4.0	9.1 ± 7.4	0.208
IL-8 (n = 10)	10.1 ± 3.4	25.9 ± 23.5	0.208
IL-10 (n = 10)	0.6 ± 0.3	0.8 ± 0.3	0.425
IL-22 (n = 8)	1.2 ± 0.5	1.3 ± 0.7	0.829
Immune profiling (% intact live cells)
Lymphocytes	73.1 ± 2.2	75.6 ± 5.4	0.379
CD3 T-cells	50.3 ± 4.5	46.0 ± 12.4	0.480
CD8 T-cells	21.0 ± 3.5	16.8 ± 4.1	0.113
Naïve	3.5 ± 2.7	1.9 ± 1.4	0.293
Central memory	0.6 ± 0.9	0.8 ± 0.7	0.719
Effector memory	3.8 ± 0.8	6.2 ± 1.6	0.015
Terminal effector	13.2 ± 1.9	7.9 ± 2.4	0.005
CD4 T-cells	25.8 ± 5.9	26.7 ± 9.3	0.860
Naïve	8.3 ± 7.0	3.8 ± 1.7	0.227
Central memory	5.4 ± 1.0	7.1 ± 3.4	0.317
Effector memory	4.2 ± 1.6	6.5 ± 1.9	0.081
Terminal effector	7.9 ± 3.2	9.3 ± 4.1	0.560
Gamma delta T-cells	3.1 ± 2.0	1.9 ± 0.6	0.273
MAIT & NKT CD4 cells	0.4 ± 0.2	0.6 ± 0.6	0.543
B cells	6.4 ± 3.1	6.9 ± 3.0	0.808
Naïve	5.6 ± 3.1	6.1 ± 3.1	0.806
Memory	0.6 ± 0.1	0.6 ± 0.2	0.985
Plasma blasts	0.2 ± 0.1	0.1 ± 0.1	0.832
NK cells	16.4 ± 1.7	22.7 ± 8.1	0.156
Early NK	2.5 ± 0.8	3.3 ± 1.2	0.264
Late NK	13.9 ± 1.0	19.5 ± 7.4	0.169
Monocytes	15.8 ± 2.9	15.2 ± 2.7	0.737
Classical	13.5 ± 2.8	13.0 ± 2.5	0.760
Transitional	1.6 ± 0.7	1.6 ± 0.6	0.851
Nonclassical	0.6 ± 0.6	0.6 ± 0.6	0.967
Dendritic cells	1.3 ± 0.2	1.1 ± 0.5	0.446
pDC	0.3 ± 0.1	0.3 ± 0.1	0.247
mDC	1.0 ± 0.2	0.9 ± 0.4	0.585
Granulocytes	1.0 ± 0.6	1.0 ± 1.3	0.998
Neutrophils	0.4 ± 0.4	0.2 ± 0.1	0.190
Basophils	0.3 ± 0.3	0.6 ± 1.0	0.630
Eosinophils	0.0 ± 0.0	0.0 ± 0.0	0.242
CD66b neutrophils	0.3 ± 0.1	0.3 ± 0.2	0.876